Loading...
Loading...
EQRXW| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 98.2M |
| Operating I/L | -101.8M |
| Other Income/Expense | 19.2M |
| Interest Income | 15.4M |
| Pretax | -82.6M |
| Income Tax Expense | -19.2M |
| Net Income/Loss | -63.3M |
EQRx, Inc. is a pharmaceutical company focused on developing innovative medicines for the treatment of oncology and immune-inflammatory diseases. The company's product pipeline includes Aumolertinib, Sugemalimab, Lerociclib, and EQ176, targeting various types of cancer such as non-small cell lung cancer, breast cancer, and liver cancer. EQRx, Inc. generates revenue through the development and commercialization of these novel therapies, aiming to address unmet medical needs and improve patient outcomes.
